Recent research has concluded that a group of men suffering from prostate cancer havebenefited with a new drug even though they had poor prognosis before the trial.
In a recent study in men suffering from end-stage prostate cancer, it has been found that about 5% of the patients responded to the treatment with pembrolizumab well and survival rates increased by years.
Some patients were found to have mutaions in their DNA repairing genes. These type of patients were benefited the most with Immunotherapy trial.
The Institute of Cancer Research in London along with The Royal Marsden Foundation Trust conducted a trial in 258 men having advanced prostate cancer who were not responding to other modalities of treatment such as docetaxel chemotherapy and androgen deprivation.
Leading journal on cancer Clinical Oncology has published this research.
There was evidence of shrinkage or disappearance of the tumor on scans in about 5 percent of the patients and a reduction in prostate-specific antigen (PSA) level in about 19 percent.
Currently trials are conducted on larger level to confirm if patients should receive pembrolizumab as standard treatment.